How PointMan testing kits could advance non-invasive cancer diagnostics

Sonia Nicholas, SelectScience's Clinical Editor spoke to Dr Ricardo Del Sol, Senior Lecturer at the College of Medicine, Institute of Life Science at Swansea University, UK, about using PointMan™ DNA Enrichment Kits and how working with EKF Diagnostics is leading to new advances in cancer diagnostics. Read the full interview here.

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

TR-1: Standard form for notification of major holdings

Notification of major holdings.

2017 Final Results

EKF Diagnostics announces its final results for the year ended 31 December 2017.

Notice of results - Investor results presentation

EKF Diagnostics announces that it will release its preliminary results for the year ended 31 December 2017 on Wednesday 14 March 2018.

Trading update

EKF Diagnostics provides shareholders with the following update on current trading.

Total voting rights

As at 29 December 2017, the Company's total issued share capital consists of 457,554,636 ordinary shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company holds no Ordinary Shares in treasury.